Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: E7080 Clear all

Conditions: Renal Cell Carcinoma Stage IV
Interventions: mHealth Smart Phone Application, eHEALS digital literacy test, Weekly Quiz, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire, Patient Post Intervention Survey; Other · Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Interventions: favezelimab/pembrolizumab, pembrolizumab, lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more

Conditions: Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Interventions: AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay; Biological · Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatocellular Carcinoma
Interventions: Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib; Drug
Lead sponsor: CStone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Coronado, California • Rialto, California • Baltimore, Maryland + 2 more

Conditions: Advanced Malignancies
Interventions: Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Miami, Florida • New York, New York • Nashville, Tennessee + 1 more

Conditions: Stage IV Melanoma
Interventions: Lenvatinib, Dacarbazine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Hagerstown, Maryland • Albany, New York • Greenville, South Carolina + 2 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Lenvatinib, Everolimus; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 14
States / cities: Tucson, Arizona • Orange, California • San Diego, California + 11 more

Conditions: Urothelial Carcinoma
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 21
States / cities: Gilbert, Arizona • Clovis, California • Orange, California + 18 more

Conditions: Neoplasms
Interventions: Erlotinib, Lenvatinib, Axitinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: HOPE; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Advanced Melanoma
Interventions: lenvatinib, pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Chandler, Arizona • Santa Monica, California • Park Ridge, Illinois + 3 more

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Cabozantinib, Everolimus, Lenvatinib, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas • Charlottesville, Virginia

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 28
States / cities: Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more

Conditions: Renal Cell Carcinoma
Interventions: Cabozantinib, Ipilimumab, Nivolumab, Lenvatinib, Everolimus; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Ipilimumab, Sorafenib, lenvatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 15
States / cities: Tucson, Arizona • Coronado, California • Duarte, California + 12 more

Conditions: Endometrial Neoplasms
Interventions: Lenvatinib, Pembrolizumab, Paclitaxel, Carboplatin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 842 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, Favezelimab, Lenvatinib, Quavonlimab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 19
States / cities: Tempe, Arizona • Sacramento, California • San Francisco, California + 15 more

Conditions: Thyroid Cancer
Interventions: Lenvatinib, Lenvatinib matching placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: La Jolla, California • San Diego, California • Torrance, California + 11 more

Conditions: Refractory Solid Tumors, Lymphomas
Interventions: Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Interventions: Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy, High-Dose Rate (HDR) Brachytherapy; Drug · Radiation
Lead sponsor: Aaron Wolfson; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Lenvatinib, Sorafenib; Drug
Lead sponsor: Eisai Limited; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 18 more

Conditions: Renal Cell Carcinoma
Interventions: Lenvatinib, Everolimus, Partial or Radical Cytoreductive Nephrectomy; Drug · Procedure
Lead sponsor: Yousef Zakharia; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Tumor, Adenocarcinoma
Interventions: Pembrolizumab, lenvatinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nonsquamous Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, Placebo matching lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 761 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Mountain View, California • New Haven, Connecticut • Fort Lauderdale, Florida + 13 more

Search by objective public record fields.

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

E7080 Food Effect Study in Healthy Subjects

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)